Codexis (CDXS)
(Delayed Data from NSDQ)
$2.69 USD
+0.01 (0.37%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $2.68 -0.01 (-0.37%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CDXS 2.69 +0.01(0.37%)
Will CDXS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CDXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDXS
Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates
CDXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates
Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?
Other News for CDXS
Codexis to Report Second Quarter 2025 Financial Results on August 13 | CDXS Stock News
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
Opaleye Management Inc. Increases Stake in Codexis Inc.
Opaleye Management Makes a Bold Move with Codexis Stock Purchase!